Safety and Efficacy of Ibutilide in Heart Transplant Recipients

José A. Tallaj, Veronica Franco, Barry K. Rayburn, Salpy V. Pamboukian, Raymond L. Benza, James K. Kirklin, David C. McGiffin, Melissa Smallfield, Robert C. Bourge

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


In this report we describe our experience with ibutilide, a relatively new Class III anti-arrhythmic agent, in 8 heart transplant patients with supraventricular tachycardia in various settings (3 patients with rejection, 2 after endomyocardial biopsy). Ibutilide treatment was successful in all patients, with the arrhythmia recurring early in 1 patient. There were no complications.

Original languageEnglish
Pages (from-to)505-507
Number of pages3
JournalJournal of Heart and Lung Transplantation
Issue number5
Publication statusPublished - 1 May 2009
Externally publishedYes

Cite this

Tallaj, J. A., Franco, V., Rayburn, B. K., Pamboukian, S. V., Benza, R. L., Kirklin, J. K., McGiffin, D. C., Smallfield, M., & Bourge, R. C. (2009). Safety and Efficacy of Ibutilide in Heart Transplant Recipients. Journal of Heart and Lung Transplantation, 28(5), 505-507.